First Trust Advisors’s Halozyme HALO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $111M | Sell |
1,417,063
-65,277
| -4% | -$4.45M | 0.07% | 362 |
|
|
2026
Q1 | $95.8M | Buy |
1,482,340
+470,558
| +47% | +$33.2M | 0.07% | 360 |
|
|
2025
Q4 | $68.1M | Buy |
1,011,782
+235,371
| +30% | +$15.8M | 0.05% | 444 |
|
|
2025
Q3 | $56.9M | Buy |
776,411
+10,493
| +1% | +$697K | 0.04% | 516 |
|
|
2025
Q2 | $39.8M | Sell |
765,918
-37,776
| -5% | -$2.15M | 0.03% | 656 |
|
|
2025
Q1 | $51.3M | Sell |
803,694
-55,878
| -7% | -$3.25M | 0.05% | 530 |
|
|
2024
Q4 | $41.1M | Sell |
859,572
-17,291
| -2% | -$887K | 0.04% | 616 |
|
|
2024
Q3 | $50.2M | Sell |
876,863
-149,303
| -15% | -$8.56M | 0.05% | 498 |
|
|
2024
Q2 | $53.7M | Sell |
1,026,166
-168,298
| -14% | -$7.38M | 0.05% | 427 |
|
|
2024
Q1 | $48.6M | Buy |
1,194,464
+1,102,623
| +1,201% | +$41.3M | 0.05% | 479 |
|
|
2023
Q4 | $3.39M | Buy |
91,841
+84,288
| +1,116% | +$3.17M | ﹤0.01% | 1496 |
|
|
2023
Q3 | $289K | Buy |
7,553
+1,941
| +35% | +$79.5K | ﹤0.01% | 2247 |
|
|
2023
Q2 | $202K | Sell |
5,612
-99,668
| -95% | -$3.4M | ﹤0.01% | 2294 |
|
|
2023
Q1 | $4.02M | Buy |
105,280
+51,110
| +94% | +$2.4M | ﹤0.01% | 1345 |
|
|
2022
Q4 | $3.08M | Sell |
54,170
-56,923
| -51% | -$2.91M | ﹤0.01% | 1494 |
|
|
2022
Q3 | $4.39M | Buy |
111,093
+30,639
| +38% | +$1.35M | 0.01% | 1256 |
|
|
2022
Q2 | $3.54M | Buy |
80,454
+28,865
| +56% | +$1.25M | ﹤0.01% | 1446 |
|
|
2022
Q1 | $2.06M | Sell |
51,589
-5,138
| -9% | -$183K | ﹤0.01% | 1762 |
|
|
2021
Q4 | $2.28M | Sell |
56,727
-65,434
| -54% | -$2.44M | ﹤0.01% | 1736 |
|
|
2021
Q3 | $4.97M | Buy |
122,161
+37,835
| +45% | +$1.58M | 0.01% | 1311 |
|
|
2021
Q2 | $3.83M | Sell |
84,326
-54,754
| -39% | -$2.42M | ﹤0.01% | 1512 |
|
|
2021
Q1 | $5.8M | Buy |
139,080
+56,213
| +68% | +$2.57M | 0.01% | 1149 |
|
|
2020
Q4 | $3.54M | Buy |
82,867
+23,189
| +39% | +$834K | ﹤0.01% | 1275 |
|
|
2020
Q3 | $1.57M | Sell |
59,678
-40,388
| -40% | -$1.12M | ﹤0.01% | 1508 |
|
|
2020
Q2 | $2.68M | Buy |
100,066
+86,443
| +635% | +$1.95M | ﹤0.01% | 1233 |
|
|
2020
Q1 | $245K | Buy |
+13,623
| New | +$259K | ﹤0.01% | 2135 |
|
|
2019
Q4 | – | Sell |
-43,140
| Closed | -$669K | – | 2416 |
|
|
2019
Q3 | $669K | Buy |
+43,140
| New | +$711K | ﹤0.01% | 2021 |
|
|
2019
Q2 | – | Sell |
-97,659
| Closed | -$1.57M | – | 2465 |
|
|
2019
Q1 | $1.57M | Buy |
97,659
+15,320
| +19% | +$248K | ﹤0.01% | 1656 |
|
|
2018
Q4 | $1.21M | Buy |
82,339
+46,301
| +128% | +$739K | ﹤0.01% | 1752 |
|
|
2018
Q3 | $655K | Sell |
36,038
-122,943
| -77% | -$2.15M | ﹤0.01% | 2100 |
|
|
2018
Q2 | $2.68M | Buy |
158,981
+74,161
| +87% | +$1.4M | 0.01% | 1466 |
|
|
2018
Q1 | $1.66M | Buy |
84,820
+6,569
| +8% | +$127K | ﹤0.01% | 1576 |
|
|
2017
Q4 | $1.58M | Buy |
78,251
+40,710
| +108% | +$748K | ﹤0.01% | 1651 |
|
|
2017
Q3 | $652K | Sell |
37,541
-33,565
| -47% | -$455K | ﹤0.01% | 1999 |
|
|
2017
Q2 | $912K | Buy |
71,106
+55,437
| +354% | +$740K | ﹤0.01% | 1883 |
|
|
2017
Q1 | $203K | Sell |
15,669
-92,118
| -85% | -$1.16M | ﹤0.01% | 2306 |
|
|
2016
Q4 | $1.06M | Buy |
+107,787
| New | +$1.18M | ﹤0.01% | 1785 |
|
Other funds holding HALO
First Trust Advisors's HALO Position: Q2 2026 in Review
First Trust Advisors reduced its Halozyme (HALO) stake by 4.4% in Q2 2026, selling an estimated $4.45M and leaving 1,417,063 shares worth $111M. The position accounts for 0.07% of the portfolio, ranked #362.
First Trust Advisors first reported a position in HALO in Q4 2016 and has held it in 37 quarters since. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.
- First Trust Advisors held 1,417,063 shares of Halozyme worth $111M as of Q2 2026.
- First Trust Advisors sold 65,277 Halozyme shares in Q2 2026, an estimated $4.45M.
- Halozyme made up 0.07% of First Trust Advisors's portfolio in Q2 2026, its #362 holding.
- First Trust Advisors first reported a position in Halozyme in Q4 2016 and has held it in 37 quarters since.
- 668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.